Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Veterinary Vaccines Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Veterinary Vaccines Market

Chapter 4. Market Overview
4.1. Introduction
    4.1.1. Product Overview
4.2. Market Dynamics
    4.2.1. Drivers
    4.2.2. Restraints
    4.2.3. Opportunities
4.3. Global Veterinary Vaccines Market Analysis and Forecasts, 2016–2026
    4.3.1. Market Revenue Projection (US$ Mn)

Chapter 5. Market Outlook
5.1. White Space Analysis
5.2. Disease Outbreak Globally : Livestock Animal Disease
5.3. Main (Vector Borne Disease) VBDs affecting livestock
5.4. Animal Population (Mn), by Key Country in 2017
5.5. Top Ten Countries with Highest Number of Vets and Vet Clinics, 2016
5.6. Pet Ownership (%) by Key Country, 2016
5.7. Key Merger & Acquisition in Animal Health Industry
5.8. Regulatory Scenario by Region

Chapter 6. Global Veterinary Vaccines Market Analysis and Forecasts, by Technology
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Technology, 2017–2026
    6.3.1. Inactivated Vaccines
    6.3.2. Conjugate Vaccines
    6.3.3. Live Attenuated Vaccines
    6.3.4. Toxoid Vaccines
    6.3.5. Other Vaccines
6.4. Market Attractiveness, by Technology

Chapter 7. Global Veterinary Vaccines Market Analysis and Forecasts, by Animal
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Animal, 2017–2026
    7.3.1. Livestock Animal Vaccines
    7.3.2. Companion Animal Vaccines
7.4. Market Attractiveness, by Animal

Chapter 8. Global Veterinary Vaccines Market Analysis and Forecasts, by Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
    8.2.1. North America
    8.2.2. Europe
    8.2.3. Asia Pacific
    8.2.4. Latin America
    8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Veterinary Vaccines Market Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017–2026
    9.1.1. U.S.
    9.1.2. Canada
9.2. Market Value Share Analysis, by Technology, 2017–2026
9.3. Market Value Forecast, by Technology, 2016–2026
    9.3.1. Inactivated Vaccines
    9.3.2. Conjugate Vaccines
    9.3.3. Live Attenuated Vaccines
    9.3.4. Toxoid Vaccines
    9.3.5. Other Vaccines
9.4. Market Value Share Analysis, by Animal, 2017–2026
9.5. Market Value Forecast, by Animal, 2016–2026
    9.5.1. Livestock Animal Vaccines
    9.5.2. Companion Animal Vaccines
9.6. Market Attractiveness Analysis
    9.6.1. By Country
    9.6.2. By Technology
    9.6.3. By Animal

Chapter 10. Europe Veterinary Vaccines Market Analysis and Forecast
10.1. Market Value Forecast, by Country/Sub-region, 2017–2026
    10.1.1. Germany
    10.1.2. France
    10.1.3. U.K.
    10.1.4. Spain
    10.1.5. Italy
    10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Technology, 2017–2026
10.3. Market Value Forecast, by Technology, 2016–2026
    10.3.1. Inactivated Vaccines
    10.3.2. Conjugate Vaccines
    10.3.3. Live Attenuated Vaccines
    10.3.4. Toxoid Vaccines
    10.3.5. Other Vaccines
10.4. Market Value Share Analysis, by Animal, 2017–2026
10.5. Market Value Forecast, by Animal, 2016–2026
    10.5.1. Livestock Animal Vaccines
    10.5.2. Companion Animal Vaccines
10.6. Market Attractiveness Analysis
    10.6.1. By Country/Sub-region
    10.6.2. By Technology
    10.6.3. By Animal

Chapter 11. Asia Pacific Veterinary Vaccines Market Analysis and Forecast
11.1. Market Value Forecast, by Country/Sub-region, 2017–2026
    11.1.1. China
    11.1.2. Japan
    11.1.3. India
    11.1.4. Australia & New Zealand
    11.1.5. Rest of Asia Pacific
11.2. Market Value Share Analysis, by Technology, 2017–2026
11.3. Market Value Forecast, by Technology, 2016–2026
    11.3.1. Inactivated Vaccines
    11.3.2. Conjugate Vaccines
    11.3.3. Live Attenuated Vaccines
    11.3.4. Toxoid Vaccines
    11.3.5. Other Vaccines
11.4. Market Value Share Analysis, by Animal, 2017–2026
11.5. Market Value Forecast, by Animal, 2016–2026
    11.5.1. Livestock Animal Vaccines
    11.5.2. Companion Animal Vaccines
11.6. Market Attractiveness Analysis
    11.6.1. By Country/Sub-region
    11.6.2. By Technology
    11.6.3. By Animal

Chapter 12. Latin America Veterinary Vaccines Market Analysis and Forecast
12.1. Market Value Forecast, by Country/Sub-region, 2017–2026
    12.1.1. Brazil
    12.1.2. Mexico
    12.1.3. Rest of Latin America
12.2. Market Value Share Analysis, by Technology, 2017–2026
12.3. Market Value Forecast, by Technology, 2016–2026
    12.3.1. Inactivated Vaccines
    12.3.2. Conjugate Vaccines
    12.3.3. Live Attenuated Vaccines
    12.3.4. Toxoid Vaccines
    12.3.5. Other Vaccines
12.4. Market Value Share Analysis, by Animal, 2017–2026
12.5. Market Value Forecast, by Animal, 2016–2026
    12.5.1. Livestock Animal Vaccines
    12.5.2. Companion Animal Vaccines
12.6. Market Attractiveness Analysis
    12.6.1. By Country/Sub-region
    12.6.2. By Technology
    12.6.3. By Animal

Chapter 13. Middle East and Africa Veterinary Vaccines Market Analysis and Forecast
13.1. Market Value Forecast, by Country/Sub-region, 2017–2026
    13.1.1. GCC Countries
    13.1.2. South Africa
    13.1.3. Israel
    13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Technology, 2017–2026
13.3. Market Value Forecast, by Technology, 2016–2026
    13.3.1. Inactivated Vaccines
    13.3.2. Conjugate Vaccines
    13.3.3. Live Attenuated Vaccines
    13.3.4. Toxoid Vaccines
    13.3.5. Other Vaccines
13.4. Market Value Share Analysis, by Animal, 2017–2026
13.5. Market Value Forecast, by Animal, 2016–2026
    13.5.1. Livestock Animal Vaccines
    13.5.2. Companion Animal Vaccines
13.6. Market Attractiveness Analysis
    13.6.1. By Country/Sub-region
    13.6.2. By Technology
    13.6.3. By Animal

Chapter 14. Competition Landscape
14.1. Competition Matrix
    14.1.1. Eli Lilly and Company
    14.1.2. Boehringer Ingelheim GmbH
    14.1.3. Merck Animal Health
    14.1.4. Virbac
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
    14.2.1. Boehringer Ingelheim GmbH (HQ, Business Segments, Employee Strength)
           14.2.1.1. Company Details
           14.2.1.2. Company Description
           14.2.1.3. Business Overview
           14.2.1.4. SWOT Analysis
           14.2.1.5. Financial Analysis
           14.2.1.6. Strategic Overview
    14.2.2. Merck Animal Health (HQ, Business Segments, Employee Strength)
           14.2.2.1. Company Details
           14.2.2.2. Company Description
           14.2.2.3. Business Overview
           14.2.2.4. SWOT Analysis
           14.2.2.5. Strategic Overview
    14.2.3. Zoetis Inc.  (HQ, Business Segments, Employee Strength)
           14.2.3.1. Company Details
           14.2.3.2. Company Description
           14.2.3.3. Business Overview
           14.2.3.4. SWOT Analysis
           14.2.3.5. Strategic Overview
    14.2.4. Eli Lilly and Company (Elanco Animal Health) (HQ, Business Segments, Employee Strength)
           14.2.4.1. Company Details
           14.2.4.2. Company Description
           14.2.4.3. Business Overview
           14.2.4.4. SWOT Analysis
           14.2.4.5. Strategic Overview
    14.2.5. Bayer AG (HQ, Business Segments, Employee Strength)
           14.2.5.1. Company Details
           14.2.5.2. Company Description
           14.2.5.3. Business Overview
           14.2.5.4. SWOT Analysis
           14.2.5.5. Financial Analysis
           14.2.5.6. Strategic Overview
    14.2.6. Ceva Santé Animale. (HQ, Business Segments, Employee Strength)
           14.2.6.1. Company Details
           14.2.6.2. Company Description
           14.2.6.3. Business Overview
           14.2.6.4. SWOT Analysis
           14.2.6.5. Financial Analysis
           14.2.6.6. Strategic Overview
    14.2.7. Virbac (HQ, Business Segments, Employee Strength)
           14.2.7.1. Company Details
           14.2.7.2. Company Description
           14.2.7.3. Business Overview
           14.2.7.4. SWOT Analysis
           14.2.7.5. Financial Analysis
           14.2.7.6. Strategic Overview
    14.2.8. Biovac (HQ, Business Segments, Employee Strength)
           14.2.8.1. Company Details
           14.2.8.2. Company Description
           14.2.8.3. Business Overview
           14.2.8.4. SWOT Analysis
           14.2.8.5. Financial Analysis
           14.2.8.6. Strategic Overview
    14.2.9. Neogen Corporation (HQ, Business Segments, Employee Strength)
           14.2.9.1. Company Details
           14.2.9.2. Company Description
           14.2.9.3. Business Overview
           14.2.9.4. SWOT Analysis
           14.2.9.5. Strategic Overview
    14.2.10. Immucell Corporation (HQ, Business Segments, Employee Strength)
           14.2.10.1. Company Details
           14.2.10.2. Company Description
           14.2.10.3. Business Overview
           14.2.10.4. SWOT Analysis
           14.2.10.5. Strategic Overview

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote